1. Scrip
  2. >>R&D

Kancera To Pursue Ex-AZ Asset Targeting Fractalkine Into Clinic

 
• By Sukaina Virji

Swedish drug developer Kancera has exercised an exclusive option to develop a former AstraZeneca drug candidate. The small molecule shares a mechanism of action with a clinical-stage therapeutic antibody from Eisai.

Homeless dog
Abandoned by AstraZeneca, fractalkine project gets new lease of life • Source: Shutterstock

Kancera will shortly start Phase I trials with a small molecule drug candidate that inhibits the Fractalkine receptor CX3CR1. Originally developed for multiple sclerosis, the project was abandoned by AstraZeneca PLC in 2013 when AstraZeneca sold its Södertälje facility in Sweden to Acturum.

Kancera (listed on Nasdaq First North since 2011) entered an option agreement in 2015 with Acturum, and acquired the program...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.